Sonoma Pharmaceuticals Announces Record Quarterly Prescription Data
July 13 2017 - 4:05AM
Quarter ended June 30, 2017: Highest
quarterly number of prescriptions filled
Sonoma Pharmaceuticals, Inc. (NASDAQ:OCLS) (OCLSW), a specialty
pharmaceutical company that develops and markets unique and
effective solutions for the treatment of dermatological conditions
and advanced tissue care, today announced record quarterly
prescriptions filled for the company’s dermatology products.
The number of prescriptions filled during the June 2017 quarter
was 17,180, up 24% over the March 2017 quarter of 13,795, and up
46% over the June 2016 quarter of 11,787.
For the June 2017 quarter the following product lines
experienced double-digit growth over the March 2017 quarter:
- Alevicyn for atopic dermatitis up 26%
- Celacyn for scar treatment up 31%
- Mondoxyne for severe acne up 31%
- Sebuderm for seborrheic dermatitis up 42% (recently
launched)
In the fall of 2014, Sonoma announced a new strategic direction
for the company, crafted by the company’s new board and management
team, which focused on launching products into the U.S. dermatology
market with the company’s own direct sales force. This
initiative has been led by dermatology veterans, launching five
product lines and growing this business from zero to over 17,000
prescriptions filled in the June 2017 quarter.
“Since March 2015, for the last nine quarters, our average
quarter over quarter growth of prescriptions filled has been 20%,”
said Robert Miller, CFO of Sonoma Pharmaceuticals. “The primary
factors generating this growth have been 1) the number, quality and
leadership of our sales and marketing team and 2) the launches and
growth of our robust product portfolio. With the sale of our
Latin American business in October 2016 for over $20 million
dollars, we decided to use some of this cash to accelerate the
growth in dermatology by increasing the size of our sales force by
75%, from 17 to 30 representatives, with the financial goal of
driving Sonoma to breakeven as quickly as possible. We are
seeing acceleration of growth resulting from the hire of these new
and experienced sales people.”
About Sonoma Pharmaceuticals, Inc.Sonoma is a
specialty pharmaceutical company that develops and markets unique
and effective solutions for the treatment of dermatological
conditions and advanced tissue care. The company’s
products, which are sold throughout the United States and
internationally, have improved outcomes for more than five million
patients globally by reducing infections, itch, pain, scarring
and harmful inflammatory responses. The company's headquarters are
in Petaluma, California, with manufacturing operations in the
United States and Latin America. European marketing and sales
are headquartered in Roermond, Netherlands. More information can be
found at www.sonomapharma.com.
Forward-Looking StatementsExcept for historical
information herein, matters set forth in this press release
are forward-looking within the meaning of the “safe harbor”
provisions of the Private Securities Litigation Reform Act of 1995,
including statements about the commercial and technology progress
and future financial performance of Sonoma Pharmaceuticals,
Inc. and its subsidiaries (the “Company”). These forward-looking
statements are identified by the use of words such as “believe,”
“achieve,” and “strive,” among others. Forward-looking statements
in this press release are subject to certain risks and
uncertainties inherent in the Company’s business that could cause
actual results to vary, including such risks
that regulatory clinical and guideline developments may
change, scientific data may not be sufficient to meet
regulatory standards or receipt of required regulatory clearances
or approvals, clinical results may not be replicated in actual
patient settings, protection offered by the
Company’s patents and patent applications may be challenged,
invalidated or circumvented by its competitors, the available
market for the Company’s products will not be as
large as expected, the Company’s products will not be able to
penetrate one or more targeted markets, revenues will not be
sufficient to fund further development and clinical studies, the
Company may not meet its future capital needs, as well as
uncertainties relative to varying product formulations and a
multitude of diverse regulatory and marketing requirements in
different countries and municipalities, and other risks detailed
from time to time in the Company’s filings with the Securities and
Exchange Commission including its annual report on Form 10-K. The
Company disclaims any obligation to update these forward-looking
statements, except as required by law.
Sonoma Pharmaceuticals and Microcyn® Technology are trademarks
or registered trademarks of Sonoma Pharmaceuticals, Inc. All other
trademarks and service marks are the property of their respective
owners.
Media and Investor Contact:
Sonoma Pharmaceuticals, Inc.
Dan McFadden
VP of Public and Investor Relations
(425) 753-2105
dmcfadden@sonomapharma.com
Sonoma Pharmaceuticals (NASDAQ:SNOAW)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sonoma Pharmaceuticals (NASDAQ:SNOAW)
Historical Stock Chart
From Sep 2023 to Sep 2024